Reported 4 months ago
The article discusses the ongoing excitement around GLP-1 drugs in the pharma industry, particularly focusing on Eli Lilly's investment in tirzepatide production. Jefferies Biotechnology Managing Director Michael Yee identifies companies like Amgen, Scholar Rock, and Corbis as potential hidden gems in the GLP-1 trend, with positive outlooks for upcoming data releases. Wall Street continues to show interest in this sector, seeing it as a multiyear cycle with significant growth potential. Michael Yee's insights are detailed in an interview on Yahoo Finance.
Source: YAHOO